Breast cancer management: the road to today.

Cancer

Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.

Published: October 2008

When Cancer began publishing in 1948, 1 of the first articles to appear was a review of sex hormones and advanced carcinoma of the breast. Because little was then known about the biology of breast cancer, standard treatment was characterized by radical and disfiguring surgery, often with only a limited effect on long-term outcomes. Several pivotal developments in the ensuing 60 years changed this picture dramatically. The large tumors that were common at initial presentation in 1948 became increasingly uncommon with the growing use of screening mammography. It was soon suggested that these smaller tumors could be successfully treated with more conservative surgery, especially with the addition of multidrug chemotherapy and hormonal therapy as adjuvant treatments. These revolutionary developments, which have allowed many women to remain free of disease for extended periods of time, were chronicled in landmark papers that appeared in Cancer: the first clinical trial to determine whether screening mammography would improve outcomes, the early small trials comparing less invasive surgery with Halsted's radical mastectomy, the initial National Surgical Adjuvant Breast Project trial testing the efficacy of triethylenethiophosphoramide in combination with radical surgery, and the first antiestrogen trials. These articles are extraordinary not only for breaking new ground in their respective technical areas, but also for the keen insights shown by the authors into what would become important in the future.

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.23649DOI Listing

Publication Analysis

Top Keywords

breast cancer
8
screening mammography
8
breast
4
cancer management
4
management road
4
road today
4
today cancer
4
cancer began
4
began publishing
4
publishing 1948
4

Similar Publications

The implementation and side effect management of immune checkpoint inhibitors in gynecologic oncology: a JAGO/NOGGO survey.

BMC Cancer

January 2025

Young Academy of Gynecologic Oncology (JAGO), Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO), Berlin, Germany.

Background: The integration of immune checkpoint inhibitors (ICIs) into routine gynecologic cancer treatment requires a thorough understanding of how to manage immune-related adverse events (irAEs) to ensure patient safety. However, reports on real-world clinical experience in the management of ICIs in gynecologic oncology are very limited. The aim of this survey was to provide a real-world overview of the experiences and the current state of irAE management of ICIs in Germany, Switzerland, and Austria.

View Article and Find Full Text PDF

Background: Over the past twenty years, the post-cancer rehabilitation has been developed, usually in a hospital setting. Although this allows better care organization and improved security, it is perceived as stressful and restrictive by the "cancer survivor". Therefore, the transfer of benefits to everyday life is more difficult, or even uncertain.

View Article and Find Full Text PDF

Triaging mammography with artificial intelligence: an implementation study.

Breast Cancer Res Treat

January 2025

Google Health, 1600 Amphitheatre Pkwy, Mountain View, CA, 94043, USA.

Purpose: Many breast centers are unable to provide immediate results at the time of screening mammography which results in delayed patient care. Implementing artificial intelligence (AI) could identify patients who may have breast cancer and accelerate the time to diagnostic imaging and biopsy diagnosis.

Methods: In this prospective randomized, unblinded, controlled implementation study we enrolled 1000 screening participants between March 2021 and May 2022.

View Article and Find Full Text PDF

Background: The identification of circulating potential biomarkers may help earlier diagnosis of breast cancer, which is critical for effective treatment and better disease outcomes. We aimed to study the role of circ-FAF1 as a diagnostic biomarker in female breast cancer using peripheral blood samples of these patients, and to investigate the relation between circ-FAF1 and different clinicopathological features of the included patients.

Methods And Results: This case-control study enrolled 60 female breast cancer patients and 60 age-matched healthy control subjects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!